Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00487318 · ClinicalTrials.gov registry record · Phase 2

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

A Phase 2 study of Chronic Hepatitis C, sponsored by Bader, Ted, M.D..

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00487318: Completed Phase 2 study of Chronic Hepatitis C, sponsored by Bader, Ted, M.D..

NCT00487318 is a Phase 2 study of Chronic Hepatitis C that has completed, run by Bader, Ted, M.D.. The registered enrollment target is 40 participants, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00487318, a Phase 2 study of Chronic Hepatitis C, has completed, sponsored by Bader, Ted, M.D..

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.

Conditions Studied

Interventions

  • DRUG standard of care
  • DRUG fluvastatin

Study Locations (1)

Oklahoma

  • Veterans Administration Medical Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2007-06
Est. Completion 2010-10
Phase Phase 2
Bader, Ted, M.D.

6 total trials

What the finished NCT00487318 record still lists

NCT00487318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which standard of care is the first listed.

NCT00487318 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT00487318 about?

NCT00487318 is a clinical study titled "Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin". Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for...

What is the current status of trial NCT00487318?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-06. Estimated completion is 2010-10.

What conditions does trial NCT00487318 study?

This clinical trial studies the following conditions: Chronic Hepatitis C.

What interventions are being tested in trial NCT00487318?

The interventions under investigation include: standard of care (DRUG), fluvastatin (DRUG).

Who is sponsoring clinical trial NCT00487318?

This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00487318 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00487318's enrollment target sits among peer trials

40 9th of 16 higher than 7 of 16 other Chronic Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00487318, the US trial registry maintained by the National Library of Medicine. NCT00487318 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.